Top

Published in:

Open Access 01-12-2022 | Crohn's Disease | Review

The role of diosgenin in crohn’s disease

Authors: Sunday Ogundepo, Adinnu M. Chiamaka, Mercy Olatinwo, David Adepoju, Matthias Taiwo Aladesanmi, Ugwu Obiora Celestine, Kingsley Chijioke Ali, Ogochukwu Jennifer Umezinwa, Janet Olasore, Abdullahi Alausa

Published in: Clinical Phytoscience | Issue 1/2022

Abstract

Inflammatory bowel disease (IBD) is a chronic idiopathic inflammation that can grossly affect the entire gastrointestinal tract (GIT) from the mouth to the anus. Crohn’s disease is the most known type of IBD and has been the focus of attention due to its increase in prevalence worldwide. Although the etiology is yet to be elucidated, recent studies have pointed out Crohn’s disease to arise from a complex interaction between environmental influences, genetic predisposition, and altered gut microbiota, resulting in dysregulated adaptive and innate responses. The presenting hallmarks of Crohn’s disease may include weight loss, nausea, vomiting, abdominal pain, diarrhea, fever, or chills. Treatment is usually done with many approved immunosuppressive drugs and surgery. However, a promising avenue from natural compounds is a safer therapy due to its safe natural active ingredients and the strong activity it shows in the treatment and management of diseases. Diosgenin, “a major biologically active natural steroidal sapogenin found in Chinese yam,” has been widely reported as a therapeutic agent in the treatment of various classes of disorders such as hyperlipidemia, inflammation, diabetes, cancer, infection, and immunoregulation. In this review, an analysis of literature data on diosgenin employed as a therapeutic agent for the treatment of Crohn’s disease is approached, to strengthen the scientific database and curtail the dreadful impact of Crohn’s disease.

GBD 2017 Inflammatory bowel disease collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020(5):17–30. https://doi.org/10.1016/S2468-1253(19)30333-4.

Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–78.PubMedPubMedCentralCrossRef

Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. F1000Prime Rep. 2015;2(7):44. https://doi.org/10.12703/P7-44.

Peyrin-Biroulet L, Loftus EV, Colombel J, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105:289–97.PubMedCrossRef

Beaugerie L, Seksik P, Nion-Larmurier I, Gendre J, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.PubMedCrossRef

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.PubMedCrossRef

Ma J, Clemants S. A history and overview of the Flora Reipublicae Popularis Sinicae (FRPS, Flora of China, Chinese edition). 2006;55(2)451–60.

Omonigho SE, Ikenebomeh MJ. Effects of different preservative treatments on the chemical changes of pounded white yam (Dioscorea rotundata) in storage at 28±2 °C. Food Chem. 2000;68:201–9.CrossRef

Yuan SL. Research advances on chemical compositions and bioactivities of Dioscorea opposite thumb. (Chinese yam). Food Res Dev. 2008;29(3):176–9.

10.

Zhou YF, WuY ZYM, Yan YH. The manufacture and utilization of Chinese yam. Anhui Agric Sci Bull. 2004;10:65–6.

11.

Fu YC, Ferng LHA, Huang PY. Quantitative analysis of allantoin and allantoic acid in yam tuber, mucilage, skin and bulbil of the Dioscorea species. Food Chem. 2006;94:541–9.CrossRef

12.

Yang DJ, Lin JT. Effects of different storage conditions on steroidal saponins in yam (Dioscorea pseudojaponica Yamamoto) tubers. Food Chem. 2008;110:670–7.CrossRef

13.

Adedayo CB, Oboh G, Ademiluyi AO, Akindaahunsi AA. Comparative studies on antioxidant properties of some tropical Nigerian yam varieties (Dioscorea spp.). Adv Food Sci. 2011;33:28–33.

14.

Raju J, Mehta R. Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. Nutr Cancer. 2009;61:27–35.PubMedCrossRef

15.

Gupta MM, Farooqui SU, Lal RN. Distribution and variation of diosgenin in different parts of Costus speciosus. J Nat Prod. 1981;44:486–9.CrossRef

16.

Shao B, Guo H, Cui Y, Ye M, Han J, Guo D. Steroidal saponins from Smilax China and their anti-inflammatory activities. Phytochemistry. 2007;68:623–30.PubMedCrossRef

17.

Dong J, Lei C, Lu D, Wang Y. Direct biotransformation of dioscin into diosgenin in rhizome of Dioscorea zingiberensis by Penicillium dioscin. Indian J Microbiol. 2015;55(2):200–6.PubMedCrossRef

18.

Al Jasem Y, Khan M, Taha A, Thiemann T. Preparation of steroidal hormones with an emphasis on transformations of phytosterols and cholesterol—a review. Mediterranean J Chem. 2014;3(2):796–830.CrossRef

19.

Gautam S, Muthu S, Sudha W, Myriam M, Frank A, Alan K, et al. Pro-apoptotic and anti-cancer properties of diosgenin: a comprehensive and critical review. Nutrients. 2018;10:645–57. https://doi.org/10.3390/nu10050645.CrossRef

20.

Lv Y-C, Yang J, Yao F, Xie W, Tang Y-Y, Ouyang X-P, et al. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregulation of ATPbinding cassette transporter A1. Atherosclerosis. 2015;240:80–9. https://doi.org/10.1016/j.atherosclerosis.2015.02.044.CrossRefPubMed

21.

M.A. Tikhonova, C.-H. Yu, N.G. Kolosova, L.A. Gerlinskaya, S.O. Maslennikova, A.V. Yudina, T.G. Amstislavskaya, Y.-J. Ho, Comparison of behavioral and biochemical deficits in rats with hereditary defined or D-galactose-induced accelerated senescence: evaluating the protective effects of diosgenin, Pharmacol Biochem Behav 2014, (120): 7–16, https://doi.org/https://doi.org/10.1016/j.pbb.2014.01.012.

22.

Wang L, Walia B, Evans J, Gewirtz AT, Merlin D, Sitaraman SV. IL-6 induces NF-kappa B activation in the intestinal epithelia. J Immunol. 2003;171:3194–201.PubMedCrossRef

23.

Nenci A, Becker C, Wullaert A, Gareus R, van Loo G, Danese S, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557–61.PubMedCrossRef

24.

Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature. 2007;446:552–6.PubMedCrossRef

25.

Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappaB activity through induction of I kappa B synthesis. Science. 1995;270:286–90.PubMedCrossRef

26.

Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, et al. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65 / IkappaBalpha system in patients with Crohn’s disease. Gut. 1999;45:693–704.PubMedPubMedCentralCrossRef

27.

Pg HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cua DJ, Powrie F. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006;25:309–18.

28.

Schultz MButt A. Is the north to south gradient in inflammatory bowel disease a global phenomenon? Expert Rev Gastroenterol Hepatol. 2012;6(4):445–7.CrossRef

29.

Vind I, Riis L, Jess T, Knudsen E. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and county, 2003-2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006;101(6):1274–82.PubMedCrossRef

30.

Yapp T, Stenson R, Thomas G. Crohn’s disease incidence in Cardiff from 1930: an update for 1991-1995. Eur J Gastroenterol Hepatol. 2000;12(8):907–11.PubMedCrossRef

31.

Rubin G, Hungin A, Kelly P. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther. 2000;14(12):1553–9.PubMedCrossRef

32.

Loftus C, Loftus E, Harmsen S. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13(3):254–61.PubMedCrossRef

33.

Bernstein C, Wajda A, Svenson L. The epidemiology of inflammatory bowel disease in Canada: A population-based study. Am J Gastroenterol. 2006;101(7):1559–68.PubMedCrossRef

34.

Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis. 2010;4:28–62.PubMedCrossRef

35.

Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Crohn’s disease Division of Gastroenterology, cahn School of Medicine at Mount Sinai, New York City, NY, USA 2016. https://doi.org/10.1016/S0140-6736(16)31711-1

36.

Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006;12:3668–72.PubMedPubMedCentralCrossRef

37.

Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.PubMedPubMedCentralCrossRef

38.

Franke A, McGovern DPB, Barrett JC, Wang K, Radford- Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet. 2010;42:1118–25.PubMedPubMedCentralCrossRef

39.

Guo QS, Xia B, Jiang Y, Qu Y, Li J. NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J Gastroenterol. 2004;10:1069–71.PubMedPubMedCentralCrossRef

40.

Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet. 2012;380:1590–605.PubMedCrossRef

41.

Lee JC, Parkes M. Genome-wide association studies and Crohn's disease. Brief Funct Genomics. 2011;10(2):71–6.PubMedCrossRef

42.

Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJP, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867–74.PubMedCrossRef

43.

Jiang W, Wang X, Zeng B, Liu L, Tardivel A, Wei H, et al. Recognition of gut microbiota by NOD2 is essential for the homeostasis of intestinal intraepithelial lymphocytes. J Exp Med. 2013;210:2465–76.PubMedPubMedCentralCrossRef

44.

Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn’s disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut. 2009;58:882–3.PubMed

45.

Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010;16:90–7.PubMedCrossRef

46.

van Heel DA, Ghosh S, Hunt KA, Mathew CG, Forbes A, Jewell DP, et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn’s disease. Gut. 2005;54:1553–7.PubMedPubMedCentralCrossRef

47.

Brain O, Owens BMJ, Pichulik T, Allan P, Khatamzas E, Leslie A, et al. The intracellular sensor NOD2 induces microRNA-29 expression in human dendritic cells to limit IL-23 release. Immunity. 2013;39:521–36.PubMedCrossRef

48.

Kobayashi K, Inohara N, Hernandez LD, Galan JE, Núñez G, Janeway CA, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature. 2002;416:194–9.PubMedCrossRef

49.

Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinated regulation of toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol. 2007;27:6012–25.PubMedPubMedCentralCrossRef

50.

Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, Kelliher MA. NOD2 pathway activation by MDP or mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem. 2007;282:36223–9.PubMedCrossRef

51.

Hasegawa M, Fujimoto Y, Lucas PC, Nakano H, Fukase K, Núñez G, et al. A critical role of RICK/RIP2 polyubiquitination in nod-induced NF-_B activation. EMBO J. 2008;27:373–83.PubMedCrossRef

52.

Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, et al. Purification of a human monocyte- derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987;84:9233–7.PubMedPubMedCentralCrossRef

53.

Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14:6735–41.PubMedCrossRef

54.

Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12:375–91.PubMedCrossRef

55.

Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology. 2005;7:122–33.PubMedPubMedCentralCrossRef

56.

Beste MT, Pfaffle-Doyle N, Prentice EA, Morris SN, Lauffenburger DA, Isaacson KB, et al. Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Sci Transl Med. 2014;30:79–88.

57.

Tanghetti EA. The role of inflammation in the pathology of acne. J Clin Aesthet Dermatol. 2013;6:27–35.PubMedPubMedCentral

58.

Li J, Moran T, Swanson E, Julian C, Harris J, Bonen DK, et al. Regulation of IL-8 and IL-1_ expression in Crohn’s disease associated NOD2/CARD15 mutations. Hum Mol Genet. 2006;13:1715–25.CrossRef

59.

Lappalainen M, Paavola-Sakki P, Halme L, Turunen U, Fa¨rkkila¨, M., Repo, H., and Kontula, K. Novel CARD15/NOD2 mutations in Finnish patients with Crohn’s disease and their relation to phenotypic variation in vitro and in vivo. Inflamm Bowel Dis. 2008;14:176–85.PubMedCrossRef

60.

van Heel DA, Hunt KA, King K, Ghosh S, Gabe SM, Mathew CG, et al. Detection of muramyl dipeptide- sensing pathway defects in patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12:598–605.PubMedCrossRef

61.

Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.PubMedPubMedCentralCrossRef

62.

Travassos LH, Carneiro Leticia AM, Ramjeet M, Hussey S, Kim Y, Magalhães JG, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55–62.PubMedCrossRef

63.

Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462–71.PubMedCrossRef

64.

Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002;2:372–7.PubMedCrossRef

65.

Helbig KL, Nothnagel M, Hampe J, Balschun T, Nikolaus S, Schreiber S. A case-only study of gene-environment interaction between genetic susceptibility variants in NOD2 and cigarette smoking in Crohn's disease aetiology. BMC Med Genet. 2012;13:14.PubMedPubMedCentralCrossRef

66.

Amre DK, D’Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol. 2007;102(9):2016–25.PubMedCrossRef

67.

Sakamoto N, Kono S, Wakai K, et al. Epidemiology Group of the Research Committee on inflammatory bowel disease in Japan. Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis. 2005;11(2):154–63.PubMedCrossRef

68.

Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563–73.PubMedCrossRef

69.

Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156(5):350–9.PubMedPubMedCentralCrossRef

70.

García Rodríguez LA, González-Pérez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther. 2005;22(4):309–15.PubMedCrossRef

71.

Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(4):e794–803.PubMedPubMedCentralCrossRef

72.

Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103(9):2394–400.PubMedCrossRef

73.

Khalili H, Higuchi LM, Ananthakrishnan AN. Hormone therapy increases risk of ulcerative colitis but not Crohn’s disease. Gastroenterology. 2012;143(5):1199–206.PubMedCrossRef

74.

Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol. 2004;4:953–64.PubMedCrossRef

75.

Cheifetz AS. Management of active Crohn disease. JAMA. 2013;309(20):2150–8.PubMedPubMedCentralCrossRef

76.

Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut. 2001;48:503–7.PubMedPubMedCentralCrossRef

77.

Kostic AD, Xavier RJ, Gevers D. The microbiome in inflamatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–99.PubMedCrossRef

78.

Izcue A, Hue S, Buonocore S, Arancibia-Cárcamo CV, Ahern PP, Iwakura Y, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559–70.PubMedPubMedCentralCrossRef

79.

Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn’s disease. Immunol Rev. 2005;206:277–95.PubMedCrossRef

80.

Neurath MF, Weigmann B, Finotto S. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med. 2002;195:1129–43.PubMedPubMedCentralCrossRef

81.

Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn’s disease. J Immunol. 1999;163:143–7.PubMed

82.

Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn’s disease: expression and localization in intestinal mucosal cells. J Immunol. 1999;162:6829–35.PubMed

83.

Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007;56:1696–705.PubMedPubMedCentralCrossRef

84.

Dambacher J, Beigel F, Zitzmann K, et al. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut Published Online First: May 2008,30:1–12 doi:https://doi.org/10.1136/gut2007.130112.

85.

Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423–30.PubMedCrossRef

86.

Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849–61.PubMedPubMedCentralCrossRef

87.

Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17- producing T helper memory cells. Nat Immunol. 2007;8:639–46.PubMedCrossRef

88.

Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70.PubMedPubMedCentralCrossRef

89.

Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology. 2005;129:969–84.PubMedCrossRef

90.

Di Sabatino A, Rovedatti L, Kaur R, Spencer JP, Brown JT, Morisset VD, et al. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol. 2009;183:3454–62.PubMedCrossRef

91.

Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, et al. Circulating and gutresident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med. 2009;206:525–34.PubMedPubMedCentralCrossRef

92.

Hasanjani RM, Bayani M, Soleimani AS, Mohammadnia-Afrouzi M, Nouri H, Ebrahimpour S. Evaluation of CD4+ CD25+ FoxP3+ regulatory T-cells during treatment of patients with brucellosis. J Biol Regul Homeost Agents. 2016;30(3):675.

93.

Mohammadnia-Afrouzi M, Shahbazi M, Damavandi SB, Ganji GF, Ebrahimpour S. Regulatory T-cell: regulator of host defense in infection. J Mol Biol Res. 2017;7(1):9.CrossRef

94.

Li Y, Wang Y, Liu Y, Wang Y, Zuo X, Li Y, et al. The possible role of the novel cytokines IL-35 and IL-37 in inflammatory bowel disease. Mediat Inflamm. 2014;2014:10.CrossRef

95.

Liu Z, Feng B-S, Yang S-B, Chen X, Su J, Yang P-C. Interleukin (IL)-23 suppresses IL-10 in inflammatory bowel disease. J Biol Chem. 2012;287(5):3591–7.PubMedCrossRef

96.

Glocker E, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.PubMedPubMedCentralCrossRef

97.

Ishimaru N, Yamada A, Kohashi M, Arakaki R, Takahashi T, Izumi K, et al. Development of inflammatory bowel disease in long-Evans cinnamon rats based on CD4+CD25+Foxp3+ regulatory T cell dysfunction. J Immunol. 2008;180:6997–7008.PubMedCrossRef

98.

Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. F1000Prime Rep. 2015;2(7):44. https://doi.org/10.12703/P7-44.

99.

Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced self-cannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci. 2013;70:2425–41. https://doi.org/10.1007/s00018-012-1173-1174.

100.

Adolph TE, Tomczak MF, Niederreiter L, Ko H, Böck J, Martinez-Naves E, Glickman JN, Tschurtschenthaler M, Hartwig J, Hosomi S, Flak MB, Cusick JL, Kohno K, Iwawaki T, Billmann-Born S, Raine T, Bharti R, Lucius R, Kweon M, Marciniak SJ, Choi A, Hagen SJ, Schreiber S, Rosenstiel P, Kaser A, Blumberg RS. Paneth cells as a site of origin for intestinal inflammation. Nature. 2013;503:272–6.

101.

El H. Final report of the amended safety assessment of Dioscorea villosa (wild yam) root extract. Int J Toxicol. 2004;23:49–54. https://doi.org/10.1080/10915810490499055.

102.

Yang W, Wang Y, Li X, Yu P. Purification and structural characterization of Chinese yam polysaccharide and its activities. Carbohydr Polym. 2015;117:1021–7.PubMedCrossRef

103.

Xue YL, Miyakawa T, Sawanoa Y, Tanokura M. Cloning of genes and enzymatic characterizations of novel dioscorin isoforms from Dioscorea japonica. Plant Sci. 2012;183(1):14–9. https://doi.org/10.1016/j.plantsci.2011.10.021.CrossRefPubMed

104.

Choi EM, Koo SJ, Hwang JK. Immune cell stimulating activity of mucopolysaccharides isolated from yam (Dioscorea batatas). J Ethnopharmacol. 2004;91:1–6.PubMedCrossRef

105.

Yi T, Fan LL, Chen HL, et al. Comparative analysis of diosgenin in Dioscorea species and related medicinal plants by UPLC-DAD-MS. BMC Biochem. 2014;15(1):9.CrossRef

106.

Roghani-Dehkordi M, Roghani T. Baluchnejadmojarad, Diosgenin mitigates Streptozotocin diabetes-induced vascular dysfunction of the rat aorta: the involved mechanisms. J Cardiovasc Pharmacol. 2015;66:584–92.PubMedCrossRef

107.

Saravanan P, Ponmurugan MA, Deepa B. Senthilkumar, modulatory effects of diosgenin on attenuating the key enzymes activities of carbohydrate metabolism and glycogen content in streptozotocin-induced diabetic rats. Can J Diabetes. 2014;38:409–14.PubMedCrossRef

108.

Zhang J, Wang H. Morroniside protects against chronic atrophic gastritis in rat via inhibiting inflammation and apoptosis. Am J Transl Res. 2019;11(9):6016–23.

109.

Ahmed LA, Obaid AA, Zaki HF, Agha AM. Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol. 2014;740:379–87.PubMedCrossRef

110.

Pari L, Monisha P, Mohamed Jalaludeen A. Beneficial role of diosgenin on oxidative stress in aorta of streptozotocin induced diabetic rats. Eur J Pharmacol. 2012;691:143–50.PubMedCrossRef

111.

Tharaheswari M, Jayachandra Reddy N, Kumar R, Varshney KC, Kannan M, Sudha Rani S. Trigonelline and diosgenin attenuate ER stress, oxidative stressmediated damage in pancreas and enhance adipose tissue PPARgamma activity in type 2 diabetic rats. Mol Cell Biochem. 2014;396:161–74.PubMedCrossRef

112.

Wang HW, Liu HJ, Cao H, Qiao ZY, Xu YW. Diosgenin protects rats from myocardial inflammatory injury induced by ischemia-reperfusion. Med Sci Monit. 2018;24:246–53.PubMedPubMedCentralCrossRef

113.

Manivannan J, Balamurugan E, Silambarasan T, Raja B. Diosgenin improvesvascular function by increasing aortic eNOS expression, normalize dyslipidemiaand ACE activity in chronic renal failure rats. Mol Cell Biochem. 2013;384:113–20.PubMedCrossRef

114.

Blunden G, Rhodes CT. Stability of diosgenin. J Pharm Sci. 1968;57(4):602–4.PubMedCrossRef

115.

Okawara M, Tokudome Y, Todo H, Sugibayashi K, Hashimoto F. Effect of β-cyclodextrin derivatives on the diosgenin absorption in Caco-2 cell monolayer and rats. Biol Pharm Bull. 2014;37(1):54–9.PubMedCrossRef

116.

Okawara M, Tokudome Y, Todo H, Sugibayashi K, Hashimoto F. Enhancement of diosgenin distribution in the skin by cyclodextrin complexation following oral administration. Biol Pharm Bull. 2013;36(1):36–40.PubMedCrossRef

117.

Okawara M, Hashimoto F, Todo H, Sugibayashi K, Tokudome Y. Effect of liquid crystals with cyclodextrin on the bioavailability of a poorly water-soluble compound, diosgenin, after its oral administration to rats. Int J Pharm. 2014;472(2):257–61.PubMedCrossRef

118.

Cayen MN, Dvomik D. Effects of diosgenin on lipid metabolism in rats. J Lipid Res. 1979;162-174.

119.

Uchida K, Takase H, Nomura Y, Takeda K, Takeuchi N, Ishikawa Y. Changes in biliary and fecal bile acids in mice after treatments with diosgenin and beta-sitosteroiod. J Lipid Res. 1984;25:236–45.PubMedCrossRef

120.

Accatino L, Pizarro M, Solis N, Koeing CS. Effects of diosgenin, a plant derived steroid, on bile secretion and hepatocellular cholestasis induced by estrogen in rats. Hepatology. 1998;28:129–40.PubMedCrossRef

121.

Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abeg5 and abdg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol Res. 2003;26:348–52.PubMedCrossRef

122.

Nappez C, Liagre B, Beneytout JL. Changes in lipoxygenase activities in human erythroleukemia (HEL) cells during diosgenin-induced differentiation. Cancer Lett. 1995;96:133–40.PubMedCrossRef

123.

Moalic S, Liargre B, Corbiere C, Bianchi A, Dauca M, Bordji K. A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. FEBS Lett. 2001;506:225–30.PubMedCrossRef

124.

Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med. 1996;2:998–1004.PubMedCrossRef

125.

Owoade AO, Alausa AO, Adetutu A, Olorunnisola OS, Owoade AW. Phytochemical characterization and antioxidant bioactivity of Andrographis paniculate (nees). Pan Afr J Life Sci. 2021;5(2):246–56. https://doi.org/10.36108/pajols/1202.50.0220.CrossRef

126.

Alausa A, Ogundepo S, Olaleke B, Adeyemi R, Olatinwo M, Ismail A. Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. Chin Med. 2021;16(1):1. https://doi.org/10.1186/s13020-020-00418-7.CrossRefPubMedPubMedCentral

127.

Aggarwal BB. Nuclear factor-kappa B; the enemy within. Cancer Cell. 2004;6(3):203–8.PubMedCrossRef

128.

Bharti AC, Takada Y, Shishodia S, Aggarwal BB. J Biol Chem. 2004;279:6065–76.PubMedCrossRef

129.

Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286–90.PubMedCrossRef

130.

Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001;167:2911–20.PubMedCrossRef

131.

Weber CK, Liptay S, Wirth T, Adler G, Schmid RM. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000;119:1209–18.PubMedCrossRef

132.

Guidi L, Costanzo M, Ciarniello M, De Vitis I, Pioli C, Gatta L, et al. Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn’s disease patients during infliximab treatment. Int J Immunopathol Pharmacol. 2005;18:155–64.PubMedCrossRef

133.

Ogochukwu Jennifer Umezinwa, Muhammad Alfa Maali, Mohammed Yakubu Manbe, Ugwu Obiora Celestine, Nwankwo Ukechi Joy, Augustine Odibo, and Abdullahi Alausa. Promiscuous Bioactivity of Phytochemicals; AJBGMB 2021; 8 (3); 28-44. Article No: AJBGMB 68583. https://doi.org/10.9734/AJBGMB/2021/v8i330195.

134.

Eunice AA, Samuel FO, Alausa A, Zabdiel AA, Adewale B, Sarah AT, Banjo S, Ifeoluwa AP. Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus. Informatics in Medicine Unlocked. 2021;24:100617.

135.

Neurath MF. Cytokines in inflammatory bowel disease [research support, non-U S Gov’t review]. Nat Rev Immunol. 2014;14(5):329–42.PubMedCrossRef

136.

Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238.PubMedPubMedCentralCrossRef

137.

Lee SH, Kwon JE, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. Intest Res. 2018;16(1):26–42.PubMedPubMedCentralCrossRef

138.

Luo X, Yu Z, Deng C, et al. Baicalein ameliorates TNBS-induced colitis by suppressing TLR4/MyD88 signaling cascade and NLRP3 inflammasome activation in mice. Sci Rep. 2017;7(1):16374.PubMedPubMedCentralCrossRef

139.

Suzuki R, Katakura K, Fujiwara T, et al. Imiquimod induced CCR9 ameliorates murine TNBS colitis. Fukushima J Med Sci. 2016;62(2):90–100.PubMedPubMedCentralCrossRef

140.

Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E. The TNBS-induced colitis animal model: An overview. Ann Med Surg (2012). 2016;11:9–15. https://doi.org/10.1016/j.amsu.2016.07.019.

141.

Visnagri A, Kandhare AD, Kumar VS, et al. Elucidation of ameliorative effect of co enzyme Q10 in streptozotocin-induced diabetic neuropathic perturbation by modulation of electrophysiological, biochemical and behavioral markers. Biomed Aging Pathol. 2012;2(4):157–72.CrossRef

142.

Yin H, Bodhankar S, Zhang G, et al. Ameliorative effect of morin, a plant flavonoid against Freund’s complete adjuvant-induced polyarthritis in rats original article. Pharmacogn Mag. 2019;15(60):43.CrossRef

143.

Kandhare AD, Ghosh P, Ghule AE, et al. Elucidation of molecular mechanism involved in neuroprotective effect of coenzyme Q10 in alcohol-induced neuropathic pain. Fundam Clin Pharmacol. 2013;27(6):603–22.PubMedCrossRef

144.

Kruidenier L, Kuiper I, Van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease research support, non-U.S. Gov’t. J Pathol. 2003;2011:17–27.CrossRef

145.

Kruidenier L, Verspaget HW. Oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Review Aliment Pharmacol Ther. 2002;16(12):1997–2015.PubMedCrossRef

146.

Wang H-W, Liu H-J, Cao H, et al. Diosgenin protects rats from myocardial inflammatory injury induced by ischemia-reperfusion. Med Sci Monit. 2018;12(24):246–53.CrossRef

147.

Patil MVK, Kandhare AD, Bhise SD. Antiinflammatory effect of Daucus carota root on experimental colitis in rats. Int J Pharm Pharm Sci. 2012;4(1):337–43.

148.

Adil M, Kandhare AD, Ghosh P, et al. Ameliorative effect of naringin in acetaminophen-induced hepatic and renal toxicity in laboratory rats: role of FXR and KIM-1. Ren Fail. 2016;38(6):1007–20.PubMedCrossRef

149.

Ghule AE, Kandhare AD, Jadhav SS, et al. Omega-3-fatty acid adds to the protective effect of flax lignan concentrate in pressure overload-induced myocardial hypertrophy in rats via modulation of oxidative stress and apoptosis. Int Immunopharmacol. 2015;28(1):751–63.PubMedCrossRef

150.

Goswami S, Kandhare A, Zanwar AA, et al. Oral L-glutamine administration attenuated cutaneous wound healing in Wistar rats. Int Wound J. 2016;13(1):116–24.PubMedCrossRef

151.

Honmore V, Kandhare A, Zanwar AA, et al. Artemisia pallens alleviates acetaminophen induced toxicity via modulation of endogenous biomarkers. Pharm Biol. 2015;53(4):571–81.PubMedCrossRef

152.

Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer research support, N I H, extramural research support, Non-U S Gov’t. Cancer Cell. 2009;15(2):103–13.PubMedPubMedCentralCrossRef

153.

Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, IκB kinase activation and NF- κB-regulated gene expression. Oncogene. 2006;25(10):1463–73.PubMedCrossRef

154.

Cui J, Wang G, Kandhare AD, et al. Neuroprotective effect of naringin, a flavone glycoside in quinolinic acid-induced neurotoxicity: possible role of PPAR-γ, Bax/Bcl-2, and caspase-3. Food Chem Toxicol. 2018;121:95–108.PubMedCrossRef

155.

Guo G, Shi F, Zhu J, et al. Piperine, a functional food alkaloid, exhibits inhibitory potential against TNBSinduced colitis via the inhibition of IκB-α/NF-κB and induces tight junction protein (claudin-1, occludin, and ZO-1) signaling pathway in experimental mice. Exp Toxicol. 2020;39(4):477–91.CrossRef

156.

Tang X, Huang G, Zhang T, Li S. Elucidation of colon-protective efficacy of diosgenin in experimental TNBS-induced colitis: inhibition of NF-κB/ IkB-α and Bax/Caspase-1 signaling pathways. Biosci Biotechnol Biochem. 2020. https://doi.org/10.1080/09168451.2020.1776590.

157.

Raju J, Patlolla JM, Swamy MV, et al. Diosgenin, a steroid saponin of Trigonella foenum graecum (fenugreek), inhibits azoxymethane-induced aberrant crypt foci formation in F344 rats and induces apoptosis in HT-29 human colon cancer cells. Cancer Epidemiol Biomark Prev. 2004;13(8):1392–8.CrossRef

158.

Ondeykal JG, Herath KB, Jayasuriya H, Polishook JD, Bills GF, Dombrowski AW, et al. Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9:123–9.PubMedCrossRef

159.

Liu MJ, Wang Z, Ju Y, Wong RN, Wu QY. Diosgenin induces cell cycle arrest and apoptosis in human leukemia K562 cells with the disruption of Ca2+ homeostasis. Cancer Chemother Pharmacol. 2005;55:79–90.PubMedCrossRef

160.

Corbiere C, Liagre B, Terro F, Beneytout JL. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. Cell Res. 2004;14:188–96.PubMedCrossRef

161.

Costantino L, Barlocco D. STAT3 as a target for cancer drug discovery. Curr Med Chem. 2008;15:834–43.PubMedCrossRef

162.

Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59–76.PubMedPubMedCentralCrossRef

163.

Santer FR, Malinowska K, Culig Z, et al. Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 2010;17:241–53.PubMedPubMedCentralCrossRef

164.

Li Y, Deuring J, Peppelenbosch MP, et al. IL6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis. 2012;33:1889–96.PubMedCrossRef

165.

Mizoguchi E, Xavier RJ, Reinecker HC, et al. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology. 2003;125:148–61.PubMedCrossRef

166.

Greenhalgh CJ, Miller ME, Hilton DJ, et al. Suppressors of cytokine signaling: relevance to gastrointestinal function and disease. Gastroenterol. 2002;123:2064e81.CrossRef

167.

Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184:1543–51.PubMedCrossRef

168.

Yang H, Qi H, Ren J, Cui J, Li Z, Waldum HL, Cui G. Involvement of NF- κ B/IL-6 pathway in the processing of colorectal carcinogenesis in colitis mice. Int J Inflamm. 2014;2014. https://doi.org/10.1155/2014/130981.

169.

Harpel K, Leung S, Rice PF, et al. Imaging colon cancer development in mice: IL- 6 deficiency prevents adenoma in azoxymethane-treated Smad3 knockouts. Phys Med Biol. 2016;61:N60–9 [25] P. Hruz, S.M. Dann, L. Eckmann, STAT3.PubMedCrossRef

170.

Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 2001;20:2499–513.PubMedCrossRef

171.

Campbell GS, Yu CL, Jove R, Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem. 1997;272:2591–4.PubMedCrossRef

172.

Li F, Fernandez PP, Rajendran P, Hui KM, Sethi G. Diosgenin, a steroidal saponin, inhibits STAT3 signaling pathway leading to suppression of proliferation and chemosensitization of human hepatocellular carcinoma cells. Cancer Lett. 2010;292:197–207.PubMedCrossRef

173.

Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331–4.PubMedCrossRef

174.

Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J Biol Chem. 1999;274:23013–9.PubMedCrossRef

175.

Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15:283–93.PubMedPubMedCentralCrossRef

176.

Tenev T, Bohmer SA, Kaufmann R, Frese S, Bittorf T, Beckers T, et al. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factorstimulated STAT 1/3 activation in A431 cells. Eur J Cell Biol. 2000;79:261–71.PubMedCrossRef

177.

Kim H, Baumann H. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol Cell Biol. 1999;19:5326–38.PubMedPubMedCentralCrossRef

178.

Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T, et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity. 2000;12:95–105.PubMedCrossRef

179.

Servidei T, Aoki Y, Lewis SE, Symes A, Fink JS, Reeves SA. Coordinate regulation of STAT signaling and c-fos expression by the tyrosine phosphatase SHP-2. J Biol Chem. 1998;273:6233–41.PubMedCrossRef

Title: The role of diosgenin in crohn’s disease
Authors: Sunday Ogundepo
Adinnu M. Chiamaka
Mercy Olatinwo
David Adepoju
Matthias Taiwo Aladesanmi
Ugwu Obiora Celestine
Kingsley Chijioke Ali
Ogochukwu Jennifer Umezinwa
Janet Olasore
Abdullahi Alausa
Publication date: 01-12-2022
Publisher: Springer Berlin Heidelberg
Keywords: Crohn's Disease
Chronic Inflammatory Bowel Disease
Published in: Clinical Phytoscience / Issue 1/2022
Electronic ISSN: 2199-1197
DOI: https://doi.org/10.1186/s40816-022-00338-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The role of diosgenin in crohn’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Irvingia gabonensis leaf extract scavenges nitric oxide and hydrogen peroxide in vitro and modulates arsenic-induced hepatic oxidative stress in wistar rats

Pharmacoinformatic study of inhibitory potentials of selected flavonoids against papain-like protease and 3-chymotrypsin-like protease of SARS-CoV-2

Acrostichium aureum Linn: traditional use, phytochemistry and biological activity

Molecular interaction of bioactive compounds from Senecio biafrae leaf with α-amylase and α-glucosidase receptors

Flavonoid profile and antioxidant properties of Algerian common yew (Taxus baccata L.)

Phytochemical and pharmacological investigation of the ethanol extract of Byttneria pilosa Roxb.